Hormone replacement therapy increases the risk of breast leaf cancer in 3 years

report from the Fred Hutchinson Cancer Research Center in Seattle, USA, that the combination of estrogen and progesterone (CHT) after menopause significantly increases the risk of breast leaf cancer in just three years(Cancer Epideol Biomarkers Prev 2008, 17 (1): 43)previous studies have suggested that CHT applications for at least five years can lead to an increased risk of breast cancer, so what about shortening the application time? To do this, the researchers conducted a population case-control studyThe study included 324 cases of breast leaf cancer, 196 cases of breast catheter-small leaf hybrid cancer and 524 cases of breast catheterized cancer, as well as 469 population controls, diagnosed in 2000-2004Tissue samples from 83% of patients were tested by the central laboratoryThe correlation between hormone use and breast cancer risk was evaluated by the logistic regression method of multi-classification ordered reaction variableThe results showed that in patients with CHT for 3 years and currently being applied, the risk of breast lobe cancer and breast catheter small leaf cancer increased by 2.7 and 3.3 times, respectively, and was not related to thestaging, size and lymph node condition oftumorIn patients with breast catheter small leaf hybrid cancer, CHT can cause an increase in the risk of small leaf-based cancer (RATIO (OR) s 4.8, 95% confidence interval (CI) 2.1 to 11.1), but does not increase the risk of catheter-based cancer (OR.9,95% CI 0.9 to 4.1)At present, the risk of breast catheter cancer in people who applied CHT increased by 1.4 times, but there was no statisticalsignificanceThe researchers believe that the findings will not fundamentally change current hormone therapy recommendations, and that patients in need can still be applied, but should be used as slowly as possible and the dose should be as small as possible